Using mesenchymal stromal cells to treat traumatic brain injury
Official title: MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury
Run by Fondazione IRCCS San Gerardo dei Tintori · NCT06163833 · Data updated 2026-11-12
This study is testing if giving special cells through an IV can help people with severe traumatic brain injuries recover better within two weeks.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 78 (estimated) |
| Sponsor | Fondazione IRCCS San Gerardo dei Tintori Academic / other |
| Locations | 3 sites (Monza, MB and 2 other locations) |
| Status | Recruiting |
| Started | September 19, 2023 |
| Main results expected | December 2024 |
| Study ends | December 2026 |
| Registry record updated | December 11, 2023 |
| Trial ID | NCT06163833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-70 with severe TBI, as evidenced by CT scan abnormalities, and who can receive treatment within 48 hours of injury.
✕Probably not a fit
Patients with a high likelihood of death within the first 48 hours or those with significant pre-existing neurological impairments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the safety and efficacy of mesenchymal stromal cells (MSCs) administered intravenously to patients with severe traumatic brain injury (TBI) within 48 hours of injury. The study is a multicenter, double-blind, randomized, placebo-controlled phase II trial that will assess whether MSCs can reduce the levels of a biomarker associated with brain damage, neurofilament light (NFL), at 14 days post-treatment. Participants will be monitored for various clinical, neuroimaging, and biological parameters to understand the evolution of TBI and the potential benefits of MSC therapy.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients suffering from severe traumatic brain injury.
How similar studies have gone: While few clinical studies have assessed MSC therapy for TBI, preclinical data suggest promising outcomes, indicating that this approach is novel and has not been extensively tested in humans.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18-70 years * Clinical frailty index (CFI) \< 5 * Evidence of TBI confirmed by abnormalities consistent with trauma on CT scan upon admission (Marshall's CT Classification \>1) * Feasibility of study drug (MSC/placebo) administration within 48 hours from TBI * GCS ≤ 8 at recruitment and at least one pupil reactive to light * ICP monitoring already inserted or planned for clinical indications * Weight \< 100 Kg and \> 40 kg Exclusion Criteria: * Motor GCS \> 5 at recruitment * High likelihood (\> 85%) of death in the first 48 h calculated by IMPACT calculator on early admission data * Bilateral mydriasis * Opening ICP \> 40 mmHg * Known history of prior brain injury, psychiatric disorder, neurological impairment and/or deficit * Brain penetrating injury * Spinal cord injury * Previous epilepsy requiring anti-convulsant therapy * Severe organ failure (including PaO2/FiO2\<200 and shock) * Recent serious infectious process * Cancer * Immunosuppression * Human immunodeficiency virus * Positive urine pregnancy test or nursing * Known risk/history of coagulopathy and thromboembolism * Pre-existing and severe: * lung disease (such as asthma, chronic obstructive pulmonary disease), * heart dysfunction (as heart failure and reduced cardiac output), * liver insufficiency (as cirrhosis) * kidney insufficiency * and other organ severe abnormalities * Known hypersensitivity to excipients used in the formulation (Dimethyl sulfoxide (DMSO), Citrate-dextrose solution (ACD)) * Participation in a concurrent interventional study
Where it's running
-
Fondazione IRCCS San Gerardo dei Tintori
Monza, Mb, Italy Recruiting -
ASST Ospedale Papa Giovanni XXIII Bergamo
Bergamo, Italy Recruiting -
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milano
Milan, Italy Not yet recruiting
Study contacts
- Principal investigator: Giuseppe Citerio, Professor — Fondazione IRCCS San Gerardo dei Tintori
- Study coordinator: Giuseppe Citerio, Professor
- Email: giuseppe.citerio@unimib.it
- Phone: +39 0392334316
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding brain function and cognitive outcomes after traumatic brain injury
This study is trying to see how blood flow and brain health after a serious head injury affect thinking and memory recovery one year later for those who have had a moderate to severe traumatic brain injury.
-
Understanding and treating neurological deficits after brain hemorrhage.
This study looks at how often people with brain bleeding from an aneurysm experience delayed neurological problems and aims to find better ways to treat them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.